L
4.45
-0.31 (-6.51%)
| Previous Close | 4.76 |
| Open | 4.76 |
| Volume | 196,793 |
| Avg. Volume (3M) | 615,529 |
| Market Cap | 240,219,888 |
| Price / Book | 2.62 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Diluted EPS (TTM) | -3.31 |
| Total Debt/Equity (MRQ) | 10.67% |
| Current Ratio (MRQ) | 3.41 |
| Operating Cash Flow (TTM) | -88.00 M |
| Levered Free Cash Flow (TTM) | -50.43 M |
| Return on Assets (TTM) | -42.89% |
| Return on Equity (TTM) | -80.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Lexeo Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
2.1
| Analyst Consensus | 3.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.10 |
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 121.45% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Guggenheim, 574.16%) | Buy |
| Median | 20.00 (349.44%) | |
| Low | 13.00 (HC Wainwright & Co., 192.14%) | Buy |
| Average | 20.00 (349.44%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 7.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Oct 2025 | 13.00 (192.13%) | Buy | 9.60 |
| 07 Oct 2025 | 15.00 (237.08%) | Buy | 8.34 | |
| Guggenheim | 15 Oct 2025 | 30.00 (574.16%) | Buy | 8.83 |
| Chardan Capital | 07 Oct 2025 | 17.00 (282.02%) | Buy | 8.34 |
| 15 Aug 2025 | 15.00 (237.08%) | Buy | 4.72 | |
| Leerink Partners | 07 Oct 2025 | 20.00 (349.44%) | Buy | 8.34 |
| Oppenheimer | 31 Jul 2025 | 20.00 (349.44%) | Buy | 4.73 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ADLER ERIC | 8.83 | 9.58 | 6,188 | 52,104 |
| OTERO JOSE MANUEL | 8.83 | 9.58 | 3,825 | 32,189 |
| ROBERTSON JENNY | 8.83 | 9.58 | 6,374 | 53,638 |
| SEE TAI SANDI | 8.83 | 9.58 | 7,002 | 58,912 |
| TOWNSEND RICHARD NOLAN | 8.83 | 9.58 | 19,867 | 165,576 |
| Aggregate Net Quantity | 43,256 | |||
| Aggregate Net Value ($) | 362,417 | |||
| Aggregate Avg. Buy ($) | 8.83 | |||
| Aggregate Avg. Sell ($) | 9.58 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TOWNSEND RICHARD NOLAN | Officer | 17 Oct 2025 | Sell (-) | 13,133 | 9.58 | 125,814 |
| ADLER ERIC | Officer | 17 Oct 2025 | Sell (-) | 3,382 | 9.58 | 32,400 |
| OTERO JOSE MANUEL | Officer | 17 Oct 2025 | Sell (-) | 2,115 | 9.58 | 20,262 |
| ROBERTSON JENNY | Officer | 17 Oct 2025 | Sell (-) | 3,526 | 9.58 | 33,779 |
| SEE TAI SANDI | Officer | 17 Oct 2025 | Sell (-) | 3,888 | 9.58 | 37,247 |
| TOWNSEND RICHARD NOLAN | Officer | 15 Oct 2025 | Acquired (+) | 33,000 | 8.83 | 291,390 |
| ADLER ERIC | Officer | 15 Oct 2025 | Acquired (+) | 9,570 | 8.83 | 84,503 |
| OTERO JOSE MANUEL | Officer | 15 Oct 2025 | Acquired (+) | 5,940 | 8.83 | 52,450 |
| ROBERTSON JENNY | Officer | 15 Oct 2025 | Acquired (+) | 9,900 | 8.83 | 87,417 |
| SEE TAI SANDI | Officer | 15 Oct 2025 | Acquired (+) | 10,890 | 8.83 | 96,159 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |